ZYDUSLIFE

Zydus Lifesciences shares will be in focus on August 3 after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility at Zydus Biotech Park in Ahmedabad. The USFDA classified the inspection as Voluntary Action Indicated (VAI) following a Good Manufacturing Practices (GMP) surveillance inspection conducted between April 27 and May 5, 2026. Separately, the drugmaker said its board will meet on August 11 to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company also recently received approval to initiate a Phase III clinical trial of Desidustat for the treatment of anemia in patients with sickle cell disease. The 203-day study, being conducted in collaboration with the Indian Council of Medical Research (ICMR), will evaluate the efficacy and safety of the oral therapy. Zydus Lifesciences shares have traded between ₹835.85 and ₹1,181 over the past 52 weeks. The stock hit its 52-week high of ₹1,181 on July 8, 2026, and its 52-week low of ₹835.85 on April 2, 2026. At current levels, the stock is trading 4.61% below its 52-week high and 34.77% above its 52-week low.